Article
Chemistry, Medicinal
Zuqin Wang, Jie Wang, Yongjin Wang, Shuang Xiang, Hengliang Zhou, Shukai Song, Xiaojuan Song, Zhengchao Tu, Yang Zhou, Ke Ding, Zhi-Min Zhang, Zhang Zhang, Xiaoyun Lu
Summary: This study focuses on the development of new type II TRK inhibitors to combat acquired resistance mutations. Compound 10g displayed excellent potency against TRK mutants and demonstrated strong inhibition of cell proliferation. The results provide a promising lead compound for pan-anticancer drug discovery.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Oncology
Angela Gutierrez-Camino, Chantal Richer, Manon Ouimet, Claire Fuchs, Sylvie Langlois, Fida Khater, Maxime Caron, Patrick Beaulieu, Pascal St-Onge, Alain R. Bataille, Daniel Sinnett
Summary: This study conducted comprehensive genomic and transcriptomic analysis of FLT3 in 342 childhood ALL patients, and identified FLT3 mutations and their clinical implications. The study also discovered a novel FLT3 mutation and its impact on treatment response. Furthermore, FLT3 alterations were found to be associated with specific ALL subgroups.
BRITISH JOURNAL OF CANCER
(2023)
Article
Cell Biology
Frederic Ebstein, Sebastien Kuery, Victoria Most, Cory Rosenfelt, Marie-Pier Scott-Boyer, Geeske M. van Woerden, Thomas Besrard, Jonas Johannes Papendorf, Maja Studencka-Turski, Tianyun Wang, Tzung-Chien Hsieh, Richard Golnik, Dustin Baldridge, Cara Forster, Charlotte de Konink, Selina M. W. Teurlings, Virginie Vignard, Richard H. van Jaarsveld, Lesley Ades, Benjamin Cogne, Cyril Mignot, Wallid Deb, Marjolijn C. J. Jongmans, F. Sessions Cole, Marie-Jose H. van den Boogaard, Jennifer A. Wambach, Daniel J. Wegner, Sandra Yang, Vickie Hannig, Jennifer Ann Brault, Neda Zadeh, Bruce Bennetts, Boris Keren, Anne-Claire Gelineau, Zoee Powis, Meghan Towne, Kristine Bachman, Andrea Seeley, Anita E. Beck, Jennifer Morrison, Rachel Westman, Kelly Averill, Theresa Brunet, Judith Haasters, Melissa T. Carter, Matthew Osmond, Patricia G. Wheeler, Francesca Forzano, Shehla Mohammed, Yannis Trakadis, Andrea Accogli, Rachel Harrison, Yiran Guo, Hakon Hakonarson, Sophie Rondeau, Genevieve Baujat, Giulia Barcia, Rene Guenther Feichtinger, Johannes Adalbert Mayr, Martin Preisel, Frederic Laumonnier, Tilmann Kallinich, Alexej Knaus, Bertrand Isidor, Peter Krawitz, Uwe Voelker, Elke Hammer, Arnaud Droit, Evan E. Eichler, Ype Elgersma, Peter W. Hildebrand, Francois Bolduc, Elke Krueger, Stephane Bezieau
Summary: This study identified mutations in the PSMC3 gene that are associated with protein homeostasis dysfunction, leading to neurodevelopmental delay and intellectual disability. The mutations affected dendrite development in neurons and impaired learning capabilities in fruit flies, potentially through disruption of protein translocation and induction of proteotoxic stress. The findings suggest a potential link between protein homeostasis dysfunction and neurodevelopmental disorders, opening up new avenues for further research.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Robin Guo, Michael Offin, A. Rose Brannon, Jason Chang, Andrew Chow, Lukas Delasos, Jeffrey Girshman, Olivia Wilkins, Caroline G. McCarthy, Alex Makhnin, Christina Falcon, Kerry Scott, Yuan Tian, Fabiola Cecchi, Todd Hembrough, Deepu Alex, Ronglai Shen, Ryma Benayed, Bob T. Li, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Natasha Rekhtman, Paul Paik, Ahmet Zehir, Alexander Drilon
Summary: In MET exon 14-altered lung cancers treated with a MET TKI, the genomic mechanisms of primary resistance remain unknown, while MET expression is correlated with treatment benefit.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Magda Bahcall, Cloud P. Paweletz, Yanan Kuang, Luke J. Taus, Taebo Sim, Nam Doo Kim, Kshiti H. Dholakia, Christie J. Lau, Prafulla C. Gokhale, Pratik R. Chopade, Fangxin Hong, Zihan Wei, Jens Kohler, Paul T. Kirschmeier, Jiannan Guo, Sujuan Guo, Stephen Wang, Pasi A. Janne
Summary: MET-targeted therapies are effective in MET amplified and MET exon 14 deletion mutant non-small cell lung cancers, but drug resistance limits their efficacy. Combining type I and type II MET TKIs may delay and reduce the emergence of on target MET-mediated drug-resistance mutations.
MOLECULAR CANCER THERAPEUTICS
(2022)
Article
Biochemistry & Molecular Biology
Anna Tasegian, Francois Singh, Ian G. Ganley, Alastair D. Reith, Dario R. Alessi
Summary: This study compares the properties of Type I and Type II kinase inhibitors binding to LRRK2 and finds that Type II inhibitors have stronger effects on LRRK2 activity but cannot induce dephosphorylation of specific sites, suggesting different mechanisms of action depending on the conformation of LRRK2.
BIOCHEMICAL JOURNAL
(2021)
Article
Multidisciplinary Sciences
Yibo Zuo, Jiuyi He, Siying Liu, Ying Xu, Jin Liu, Caixia Qiao, Lichao Zang, Wenhuan Sun, Yukang Yuan, Hongguang Zhang, Xiangjie Chen, Lincong Jin, Ying Miao, Fan Huang, Tengfei Ren, Jun Wang, Feng Qian, Chuanwu Zhu, Wei Zhang, Yaobo Liu, Guoqiang Xu, Feng Ma, Hui Zheng
Summary: This study reveals the importance of LATS1 as a signal transmitter in regulating IFN-Ⅰ signaling activity. Activation of LATS1 promotes antiviral activity mediated by IFN-Ⅰ and controls in vivo IFN-Ⅰ signaling and host antiviral immune response.
Review
Pharmacology & Pharmacy
Margherita Ratti, Giulia Grizzi, Rodolfo Passalacqua, Andrea Lampis, Fabrizio Cereatti, Roberto Grassia, Jens Claus Hahne
Summary: Despite the efforts of the scientific community, the prognosis of metastatic colorectal cancer remains poor. NTRK rearrangements may represent a new therapeutic target for improving outcomes in mCRC. The identification of new molecular biomarkers and the development of new molecular targets could potentially lead to breakthroughs in the treatment of colorectal cancer patients.
EXPERT OPINION ON THERAPEUTIC TARGETS
(2021)
Article
Multidisciplinary Sciences
Huipeng Jiao, Laurens Wachsmuth, Simone Wolf, Juliane Lohmann, Masahiro Nagata, Goeksu Goekberk Kaya, Nikos Oikonomou, Vangelis Kondylis, Manuel Rogg, Martin Diebold, Simon E. Troeder, Branko Zevnik, Marco Prinz, Christoph Schell, George R. Young, George Kassiotis, Manolis Pasparakis
Summary: Mutations of the ADAR1 gene cause chronic activation of type I interferon responses, leading to severe diseases. The interaction between ADAR1 and another protein called ZBP1 prevents IFN activation. Deficiency or mutation of ZBP1's Z alpha domains reduces expression of IFN-stimulated genes and prevents early postnatal lethality in mice with mutated ADAR1 Z alpha domain.
Article
Clinical Neurology
Mitsuhiro Kato, Akiko Kada, Hideaki Shiraishi, Jun Tohyama, Eiji Nakagawa, Yukitoshi Takahashi, Tomoyuki Akiyama, Akiyoshi Kakita, Noriko Miyake, Atsushi Fujita, Akiko M. Saito, Yushi Inoue
Summary: Sirolimus has a certain inhibitory effect on focal seizures in patients with FCD type II, however, the reduction level did not reach statistical significance.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2022)
Article
Multidisciplinary Sciences
Tyler S. Beyett, Ciric To, David E. Heppner, Jaimin K. Rana, Anna M. Schmoker, Jaebong Jang, Dries J. H. De Clercq, Gabriel Gomez, David A. Scott, Nathanael S. Gray, Pasi A. Janne, Michael J. Eck
Summary: This study investigates the molecular mechanisms and structural basis of drug resistance in lung cancer and the combination of allosteric and ATP-competitive inhibitors to overcome resistance. The findings highlight the importance of the P-loop in the synergy between allosteric inhibitors and EGFR variants.
NATURE COMMUNICATIONS
(2022)
Article
Medicine, Research & Experimental
Christian Meisel, Bengisu Akbil, Tim Meyer, Erwin Lankes, Victor M. Corman, Olga Staudacher, Nadine Unterwalder, Uwe Kolsch, Christian Drosten, Marcus A. Mall, Tilmann Kallinich, Dirk Schnabel, Christine Goffinet, Horst von Bernuth
Summary: This study found that patients with APS-1 and preexisting neutralizing autoantibodies against IFN-alpha and IFN-omega developed only mild symptoms of COVID-19 after contracting SARS-CoV-2, without progressing to severe cases. These patients were mostly female and under the age of 26.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Biochemistry & Molecular Biology
Avigyan Naskar, Kousik K. Bhanja, Rakesh K. Roy, Niladri Patra
Summary: This study investigated the molecular insights and binding affinities of five ATP-competitive Type I inhibitors with WT and mutated LRRK2 kinase. The results showed that the larger inhibitors (comp1, comp3, and comp5) exhibited selectivity towards the mutated LRRK2 kinase, while MLi-2 demonstrated stable conformation after dihedral flipping in the mutated system.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Article
Cell Biology
Frederic Ebstein, Sebastien Kuery, Victoria Most, Cory Rosenfelt, Marie-Pier Scott-Boyer, Geeske M. van Woerden, Thomas Besrard, Jonas Johannes Papendorf, Maja Studencka-Turski, Tianyun Wang, Tzung-Chien Hsieh, Richard Golnik, Dustin Baldridge, Cara Forster, Charlotte de Konink, Selina M. W. Teurlings, Virginie Vignard, Richard H. van Jaarsveld, Lesley Ades, Benjamin Cogne, Cyril Mignot, Wallid Deb, Marjolijn C. J. Jongmans, F. Sessions Cole, Marie-Jose H. van den Boogaard, Jennifer A. Wambach, Daniel J. Wegner, Sandra Yang, Vickie Hannig, Jennifer Ann Brault, Neda Zadeh, Bruce Bennetts, Boris Keren, Anne-Claire Gelineau, Zoee Powis, Meghan Towne, Kristine Bachman, Andrea Seeley, Anita E. Beck, Jennifer Morrison, Rachel Westman, Kelly Averill, Theresa Brunet, Judith Haasters, Melissa T. Carter, Matthew Osmond, Patricia G. Wheeler, Francesca Forzano, Shehla Mohammed, Yannis Trakadis, Andrea Accogli, Rachel Harrison, Yiran Guo, Hakon Hakonarson, Sophie Rondeau, Genevieve Baujat, Giulia Barcia, Rene Guenther Feichtinger, Johannes Adalbert Mayr, Martin Preisel, Frederic Laumonnier, Tilmann Kallinich, Alexej Knaus, Bertrand Isidor, Peter Krawitz, Uwe Voelker, Elke Hammer, Arnaud Droit, Evan E. Eichler, Ype Elgersma, Peter W. Hildebrand, Francois Bolduc, Elke Krueger, Stephane Bezieau
Summary: PSMC3 variants disrupt proteasome function and cause proteotoxic stress, leading to neurodevelopmental delay and intellectual disability.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Article
Chemistry, Medicinal
Matthew P. Davies, Rocio Benitez, Concepcion Perez, Sven Jakupovic, Philip Welsby, Klaudia Rzepecka, Jane Alder, Colin Davidson, Ana Martinez, Joseph M. Hayes
Summary: The study introduces the in silico design, screening, and in vitro validation of potent GSK-3 beta type-II inhibitors, leading to the identification of highly potent nanomolar inhibitors with potential neuroprotective effects. The designed inhibitors show promise as a potential route toward more clinically effective GSK-3 beta inhibitors.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Hematology
Sunil K. Joshi, Kristin Qian, William H. Bisson, Kevin Watanabe-Smith, Ariane Huang, Daniel Bottomly, Elie Traer, Jeffrey W. Tyner, Shannon K. McWeeney, Monika A. Davare, Brian J. Druker, Cristina E. Tognon
Review
Oncology
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A. Davare
Summary: The proto-oncogene ROS1 encodes a receptor tyrosine kinase without a well-defined physiological role, and somatic chromosomal fusions involving ROS1 lead to chimeric oncoproteins that drive various cancers. Although ROS1-directed tyrosine kinase inhibitors show therapeutic efficacy, resistance mechanisms remain unclear.
NATURE REVIEWS CLINICAL ONCOLOGY
(2021)
Article
Oncology
Ezra Y. Rosen, Melissa L. Johnson, Sarah E. Clifford, Romel Somwar, Jennifer F. Kherani, Jieun Son, Arrien A. Bertram, Monika A. Davare, Eric Gladstone, Elena Ivanova, Dahlia N. Henry, Elaine M. Kelley, Mika Lin, Marina S. D. Milan, Binoj C. Nair, Elizabeth A. Olek, Jenna E. Scanlon, Morana Vojnic, Kevin Ebata, Jaclyn F. Hechtman, Bob T. Li, Lynette M. Sholl, Barry S. Taylor, Marc Ladanyi, Pasi A. Janne, S. Michael Rothenberg, Alexander Drilon, Geoffrey R. Oxnard
Summary: The RET proto-oncogene is activated by gene fusion in 1%-2% of NSCLC, while MET amplification is associated with resistance to selpercatinib. Combination therapy with selpercatinib and crizotinib can overcome MET-mediated resistance to RET inhibition.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Koichi Ogura, Romel Somwar, Julija Hmeljak, Heather Magnan, Ryma Benayed, Amir Momeni Boroujeni, Anita S. Bowman, Marissa S. Mattar, Inna Khodos, Elisa de Stanchina, Achim Jungbluth, Marina Asher, Igor Odintsov, Alifiani B. Hartono, Michael P. LaQuaglia, Emily Slotkin, Christine A. Pratilas, Sean Bong Lee, Lee Spraggon, Marc Ladanyi
Summary: In this study, it was found that EWSR1-WT1 directly activates NTRK3 expression in DSRCT cells, which are highly dependent on its activity for growth. Pharmacological targeting of NTRK3 with entrectinib significantly reduces growth of DSRCT cells both in vitro and in vivo, suggesting NTRK3 as a potential therapeutic target for DSRCT.
CLINICAL CANCER RESEARCH
(2021)
Article
Cell Biology
Takuo Hayashi, Igor Odintsov, Roger S. Smith, Kota Ishizawa, Allan J. W. Liu, Lukas Delasos, Christopher Kurzatkowski, Huichun Tai, Eric Gladstone, Morana Vojnic, Shinji Kohsaka, Ken Suzawa, Zebing Liu, Siddharth Kunte, Marissa S. Mattar, Inna Khodos, Monika A. Davare, Alexander Drilon, Emily Cheng, Elisa de Stanchina, Marc Ladanyi, Romel Somwar
Summary: The study demonstrates that cabozantinib is effective in targeting lung cancers with RET rearrangements by inhibiting tumor growth and activating specific apoptotic pathways. Additionally, cabozantinib suppresses MYC protein levels induced by RET expression, suggesting new therapeutic strategies for RET fusion-driven lung cancers. The novel RET fusion-dependent preclinical models offer valuable tools for refining current therapies and exploring new treatment approaches.
DISEASE MODELS & MECHANISMS
(2021)
Article
Oncology
Igor Odintsov, Allan J. W. Lui, Whitney J. Sisso, Eric Gladstone, Zebing Liu, Lukas Delasos, Renate I. Kurth, Exequiel M. Sisso, Morana Vojnic, Inna Khodos, Marissa S. Mattar, Elisa de Stanchina, Shawn M. Leland, Marc Ladanyi, Romel Somwar
Summary: The study demonstrates that the anti-HER3 antibody seribantumab inhibits NRG1 fusion-driven tumorigenesis in breast, lung, and ovarian cancer models, inducing apoptosis and blocking activation of ERBB family members and downstream signaling pathways. Seribantumab shows promising therapeutic potential for NRG1-rearranged cancers.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Igor Odintsov, Marissa S. Mattar, Allan J. W. Lui, Michael Offin, Christopher Kurzatkowski, Lukas Delasos, Inna Khodos, Marina Asher, Robert M. Daly, Natasha Rekhtman, Elisa de Stanchina, Gopinath Ganji, Marc Ladanyi, Romel Somwar
Summary: This study established patient-derived xenograft (PDX) and cell line models of NRG1-rearranged lung adenocarcinoma, identifying the MTOR pathway as a potential vulnerability in this cancer subset. The results suggest that targeting the MTOR pathway could be a promising therapeutic strategy for patients with NRG1 fusion-positive lung adenocarcinoma.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Alison M. Schram, Igor Odintsov, Madelyn Espinosa-Cotton, Inna Khodos, Whitney J. Sisso, Marissa S. Mattar, Allan J. W. Lui, Morana Vojnic, Sara H. Shameem, Thrusha Chauhan, Jean Torrisi, Jim Ford, Marie N. O'Connor, Cecile A. W. Geuijen, Ron C. J. Schackmann, Jeroen J. Lammerts van Bueren, Ernesto Wasserman, Elisa de Stanchina, Eileen M. O'Reilly, Marc Ladanyi, Alexander Drilon, Romel Somwar
Summary: NRG1 rearrangements are recurrent oncogenic drivers in solid tumors, and targeting HER2 and HER3 simultaneously with the bispecific antibody Zeno is an effective therapeutic strategy for NRG1 fusion-positive cancers, providing durable clinical responses for patients.
Article
Medicine, Research & Experimental
Sudarshan R. Iyer, Kevin Nusser, Kristen Jones, Pushkar Shinde, Clare Keddy, Catherine Z. Beach, Erin Aguero, Jeremy Force, Ujwal Shinde, Monika A. Davare
Summary: ROS1 gene rearrangements result in oncogenic ROS1 kinase fusion proteins, which are currently the only validated biomarkers for targeted therapy with ROS1 TKIs. We identified 34 missense mutations in the ROS1 tyrosine kinase domain and found that they have varying effects on ROS1 kinase function, including loss and increased catalytic activity. Specific point mutations within the ROS1 kinase domain, such as Asn and Gly substitutions at Asp2113, were found to be TKI-sensitive oncogenic variants. These findings demonstrate the potential of targeting these mutations with FDA-approved ROS1-TKIs.
EMBO MOLECULAR MEDICINE
(2023)
Article
Chemistry, Multidisciplinary
Jonathan C. Savage, Pushkar Shinde, Yizhou Yao, Monika A. Davare, Ujwal Shinde
Summary: By creating a chimera of Broccoli RNAs with mixed chemistries, it is possible to develop an effective RNA-based fluorescent K+ sensor that maintains structure and fluorescence properties without interference, providing linear fluorescent gain across physiological K+ concentrations.
CHEMICAL COMMUNICATIONS
(2021)
Article
Chemistry, Multidisciplinary
Jonathan C. Savage, Monika A. Davare, Ujwal Shinde
CHEMICAL COMMUNICATIONS
(2020)